公开(公告)号：US20200247890A1

公开(公告)日：2020-08-06

申请号：US16842885

申请日：2020-04-08

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Xavier Valencia ,  John P. Throup ,  Steven G. Nadler ,  Suzanne J. Suchard ,  Dominique Duchesne ,  Xiaoni Liu ,  Rong Shi ,  Diane E. Shevell ,  Jenny H. Xie ,  Marek Honczarenko

IPC: C07K16/28 ,  A61K47/60 ,  A61K39/395 ,  A61K45/06

Abstract: Methods of treating autoimmune diseases, such as systemic lupus erythematosus using domain antibodies that specifically bind human CD28 are provided. The methods may comprise at least one administration cycle comprising one dose of the domain antibody. The method reduces symptoms of systemic lupus erythematosus compared to placebo.

公开(公告)号：US20200216552A1

公开(公告)日：2020-07-09

申请号：US16795823

申请日：2020-02-20

Applicant: Bristol-Myers Squibb Company

Inventor： Marek Honczarenko ,  Vaishali Shah ,  Lixin Lang ,  Urvi Aras ,  Diane Shevell ,  Christine Kratt ,  Karen Price ,  Suzanne Suchard

IPC: C07K16/28 ,  A61K39/395 ,  A61K45/06

Abstract: Methods of treating autoimmune diseases, such as primary immune thrombocytopenia (ITP), solid organ transplant rejection, graft-related disease, pemphigus vulgaris, systemic sclerosis, and myasthenia gravis using antibody polypeptides that specifically bind human CD40L are provided. The antibody polypeptides do not activate platelets. The methods may comprise at least one administration cycle comprising one dose of the antibody polypeptide. The dose may be administered intravenously at a dose from about 75 mg to about 1500 mg. The method normalizes platelet counts in the human patient.

公开(公告)号：US11912769B2

公开(公告)日：2024-02-27

申请号：US17584207

申请日：2022-01-25

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Xavier Valencia ,  John P. Throup ,  Steven G. Nadler ,  Suzanne J. Suchard ,  Dominique Duchesne ,  Xiaoni Liu ,  Rong Shi ,  Diane E. Shevell ,  Jenny H. Xie ,  Marek Honczarenko

IPC: A61K39/395 ,  C07K16/28 ,  A61K47/60 ,  A61K45/06 ,  A61K39/00

CPC classification number: C07K16/2818 ,  A61K39/3955 ,  A61K45/06 ,  A61K47/60 ,  A61K2039/505 ,  A61K2039/54 ,  A61K2039/545 ,  C07K2317/24 ,  C07K2317/565 ,  C07K2317/569 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94 ,  C07K2319/31

Abstract: Methods of treating autoimmune diseases, such as systemic lupus erythematosus using domain antibodies that specifically bind human CD28 are provided. The methods may comprise at least one administration cycle comprising one dose of the domain antibody. The method reduces symptoms of systemic lupus erythematosus compared to placebo.

公开(公告)号：US20220144951A1

公开(公告)日：2022-05-12

申请号：US17584207

申请日：2022-01-25

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Xavier Valencia ,  John P. Throup ,  Steven G. Nadler ,  Suzanne J. Suchard ,  Dominique Duchesne ,  Xiaoni Liu ,  Rong Shi ,  Diane E. Shevell ,  Jenny H. Xie ,  Marek Honczarenko

IPC: C07K16/28 ,  A61K47/60 ,  A61K39/395 ,  A61K45/06

Abstract: Methods of treating autoimmune diseases, such as systemic lupus erythematosus using domain antibodies that specifically bind human CD28 are provided. The methods may comprise at least one administration cycle comprising one dose of the domain antibody. The method reduces symptoms of systemic lupus erythematosus compared to placebo.

公开(公告)号：US11267888B2

公开(公告)日：2022-03-08

申请号：US16842885

申请日：2020-04-08

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Xavier Valencia ,  John P. Throup ,  Steven G. Nadler ,  Suzanne J. Suchard ,  Dominique Duchesne ,  Xiaoni Liu ,  Rong Shi ,  Diane E. Shevell ,  Jenny H. Xie ,  Marek Honczarenko

IPC: A61K39/395 ,  C07K16/28 ,  A61K47/60 ,  A61K45/06 ,  A61K39/00

Abstract: Methods of treating autoimmune diseases, such as systemic lupus erythematosus using domain antibodies that specifically bind human CD28 are provided. The methods may comprise at least one administration cycle comprising one dose of the domain antibody. The method reduces symptoms of systemic lupus erythematosus compared to placebo.

公开(公告)号：US11466091B2

公开(公告)日：2022-10-11

申请号：US16795823

申请日：2020-02-20

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Marek Honczarenko ,  Vaishali Shah ,  Lixin Lang ,  Urvi Aras ,  Diane Shevell ,  Christine Kratt ,  Karen Price ,  Suzanne Suchard

IPC: C07K16/28 ,  A61K39/395 ,  A61K45/06 ,  A61K39/00

Abstract: Methods of treating autoimmune diseases, such as primary immune thrombocytopenia (ITP), solid organ transplant rejection, graft-related disease, pemphigus vulgaris, systemic sclerosis, and myasthenia gravis using antibody polypeptides that specifically bind human CD40L are provided. The antibody polypeptides do not activate platelets. The methods may comprise at least one administration cycle comprising one dose of the antibody polypeptide. The dose may be administered intravenously at a dose from about 75 mg to about 1500 mg. The method normalizes platelet counts in the human patient.

公开(公告)号：US10435475B2

公开(公告)日：2019-10-08

申请号：US15118279

申请日：2015-03-09

Applicant: Bristol-Myers Squibb Company

Inventor： Marek Honczarenko ,  Vaishali Shah ,  Xiaoni Liu ,  Wendy L. Trigona ,  Rong Shi ,  Suzanne J. Suchard ,  Karen D. Price ,  Linda M. Gustavson

IPC: A61K39/395 ,  C07K16/28 ,  A61K47/60 ,  A61K39/00

Abstract: A method of treating an inflammatory bowel disease is provided. The method comprises administration of an antibody polypeptide that specifically binds a novel epitope of human CD40. The antibody polypeptides do not exhibit CD40 agonist activity. The antibody polypeptides may be fusions of a domain antibody (dAb) comprising a single VL or VH domain and an Fc domain.

公开(公告)号：US20170240636A1

公开(公告)日：2017-08-24

申请号：US15515461

申请日：2015-09-30

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Xavier Valencia ,  John P. Throup ,  Steven G. Nadler ,  Suzamme J. Suchard ,  Dominique Duchesne ,  Xiaoni Liu ,  Rong Shi ,  Diane E. Shevell ,  Jenny H. Xie ,  Marek Honczarenko

IPC: C07K16/28 ,  A61K45/06 ,  A61K39/395

CPC classification number: C07K16/2818 ,  A61K39/3955 ,  A61K45/06 ,  A61K47/60 ,  A61K2039/505 ,  A61K2039/54 ,  A61K2039/545 ,  C07K2317/24 ,  C07K2317/565 ,  C07K2317/569 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94 ,  C07K2319/31

Abstract: Methods of treating autoimmune diseases, such as systemic lupus erythematosus using domain antibodies that specifically bind human CD28 are provided. The methods may comprise at least one administration cycle comprising one dose of the domain antibody. The method reduces symptoms of systemic lupus erythematosus compared to placebo.